IL261132A - Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof - Google Patents

Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Info

Publication number
IL261132A
IL261132A IL261132A IL26113218A IL261132A IL 261132 A IL261132 A IL 261132A IL 261132 A IL261132 A IL 261132A IL 26113218 A IL26113218 A IL 26113218A IL 261132 A IL261132 A IL 261132A
Authority
IL
Israel
Prior art keywords
preparation
methods
cannabis oil
powders produced
preparations based
Prior art date
Application number
IL261132A
Other languages
English (en)
Hebrew (he)
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority to IL261132A priority Critical patent/IL261132A/en
Publication of IL261132A publication Critical patent/IL261132A/en
Priority to CN201980067584.5A priority patent/CN113473965A/zh
Priority to JP2021547984A priority patent/JP2021535935A/ja
Priority to CA3086887A priority patent/CA3086887C/en
Priority to AU2019322212A priority patent/AU2019322212B2/en
Priority to US16/958,341 priority patent/US11712430B2/en
Priority to EP19714807.5A priority patent/EP3716946A1/en
Priority to PCT/IL2019/050268 priority patent/WO2020035850A1/en
Priority to BR112021009869A priority patent/BR112021009869A2/pt
Priority to IL275430A priority patent/IL275430A/en
Priority to CONC2021/0007647A priority patent/CO2021007647A2/es
Priority to US18/209,954 priority patent/US20230321031A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL261132A 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof IL261132A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
BR112021009869A BR112021009869A2 (pt) 2018-08-13 2019-03-11 Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste
AU2019322212A AU2019322212B2 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
JP2021547984A JP2021535935A (ja) 2018-08-13 2019-03-11 ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用
CA3086887A CA3086887C (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
CN201980067584.5A CN113473965A (zh) 2018-08-13 2019-03-11 通过纳米乳化配制的大麻油粉末、其产生方法和用途
US16/958,341 US11712430B2 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsification, methods of producing and uses thereof
EP19714807.5A EP3716946A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
IL275430A IL275430A (en) 2018-08-13 2020-06-17 Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use
CONC2021/0007647A CO2021007647A2 (es) 2018-08-13 2021-06-10 Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos
US18/209,954 US20230321031A1 (en) 2018-08-13 2023-06-14 Formulated Cannabis Oil Powder By Nanoemulsifycation, Methods Of Producing And Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (1)

Publication Number Publication Date
IL261132A true IL261132A (en) 2018-11-04

Family

ID=63998426

Family Applications (2)

Application Number Title Priority Date Filing Date
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
IL275430A IL275430A (en) 2018-08-13 2020-06-17 Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL275430A IL275430A (en) 2018-08-13 2020-06-17 Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use

Country Status (9)

Country Link
US (2) US11712430B2 (https=)
EP (1) EP3716946A1 (https=)
JP (1) JP2021535935A (https=)
CN (1) CN113473965A (https=)
AU (1) AU2019322212B2 (https=)
BR (1) BR112021009869A2 (https=)
CO (1) CO2021007647A2 (https=)
IL (2) IL261132A (https=)
WO (1) WO2020035850A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138630A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
CN114245739A (zh) * 2019-08-12 2022-03-25 腾思凯真私人有限公司 大麻二酚口腔崩解片
KR20230047095A (ko) 2020-07-29 2023-04-06 카낙 테크놀로지스, 엘엘씨 치료용 친유성 활성물질의 개선된 전달을 위한 약제학적 조성물
KR20220128405A (ko) * 2020-07-29 2022-09-20 카낙 테크놀로지스, 엘엘씨 화장용 사용을 위한 친지성 물질의 개선된 포뮬레이션
IL293086A (en) 2020-07-29 2022-07-01 Karnak Tech Llc Formulations of orally administered lipophilic dietary supplements and beneficial oils
CA3188864A1 (en) * 2020-08-14 2022-02-17 Ori LIEBERMAN Dosing capsule made from cannabis-derived resin and methods of making the same
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
AU2024305502A1 (en) 2023-06-16 2026-01-08 Pico Ip, Llc A process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026037496A1 (en) * 2024-08-14 2026-02-19 Tetra Pharm Technologies A self-emulsifying solid composition comprising a cannabinoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
JP6247685B2 (ja) 2012-05-16 2017-12-13 メワ・シン 実質的に水不溶性の薬物の送達のための医薬組成物
WO2015171445A1 (en) 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
WO2016147186A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
AU2016347651A1 (en) * 2015-10-26 2018-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Novel cannabinoid formulations
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物
JP2020514282A (ja) * 2016-12-20 2020-05-21 ティルレイ，インコーポレイティド 新規カンナビノイド組成物および使用方法
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo

Also Published As

Publication number Publication date
US11712430B2 (en) 2023-08-01
CO2021007647A2 (es) 2021-08-30
CA3086887A1 (en) 2020-02-20
AU2019322212B2 (en) 2022-09-29
AU2019322212A1 (en) 2021-04-08
IL275430A (en) 2020-08-31
CN113473965A (zh) 2021-10-01
JP2021535935A (ja) 2021-12-23
EP3716946A1 (en) 2020-10-07
US20210059975A1 (en) 2021-03-04
BR112021009869A2 (pt) 2022-05-17
US20230321031A1 (en) 2023-10-12
WO2020035850A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
IL261132A (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
SG11202003782XA (en) Triple-chain antibody, method for preparation and use thereof
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
IL272089B1 (en) Compounds, compositions and methods
IL262346A (en) Method of making cannabis oil hydrophilic using emulsifiers and related cannabinold compositions
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
EP3878869A4 (en) NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
WO2018109174A3 (en) Il-11 antibodies
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
KR102457098B9 (ko) 림프구를 형질도입시키기 위한 방법 및 조성물, 및 이의 조절된 확장
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
WO2018109170A3 (en) Il-11ra antibodies
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
SG10201803042PA (en) Anti-tim-3 antibodies
IL282178A (en) Products, uses & methods
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MY191581A (en) Anti-pd-1 antibodies
HUE054037T2 (hu) CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
CL2018002543A1 (es) Anticuerpos gitr, metodos y usos.
SG10201907901XA (en) Antibodies, uses & methods
IL290608A (en) Cannabinoid compositions, methods of making same and uses thereof